Home/Filings/4/0000899243-20-017885
4//SEC Filing

O'Leary James J 4

Accession 0000899243-20-017885

CIK 0001805890other

Filed

Jun 29, 8:00 PM ET

Accepted

Jun 30, 6:47 AM ET

Size

10.4 KB

Accession

0000899243-20-017885

Insider Transaction Report

Form 4
Period: 2020-06-25
O'Leary James J
Chief Medical Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2020-03-16+351,921351,921 total
    Exercise: $4.44Exp: 2030-03-16Non-Voting Common Shares (351,921 underlying)
  • Award

    Stock Option (Right to Buy)

    2020-06-25+60,85260,852 total
    Exercise: $17.00Exp: 2030-06-25Common Shares (60,852 underlying)
  • Award

    Stock Option (Right to Buy)

    2020-06-25+26,97126,971 total
    Exercise: $17.00Exp: 2030-06-18Common Shares (26,971 underlying)
Footnotes (3)
  • [F1]25% of the shares subject to this option shall vest and become exercisable on March 16, 2021, with the remainder vesting in 36 substantially equal monthly installments thereafter. Prior to closing of the Issuer's initial public offering, such Non-Voting Common Shares will convert into Voting Common Shares and subsequently into Common Shares on a one-for-one basis.
  • [F2]25% of the shares subject to this option shall vest and become exercisable on June 18, 2021, with the remainder vesting in 36 substantially equal monthly installments thereafter.
  • [F3]25% of the shares subject to this option shall vest and become exercisable on June 25, 2021, with the remainder vesting in 36 substantially equal monthly installments thereafter.

Issuer

Fusion Pharmaceuticals Inc.

CIK 0001805890

Entity typeother

Related Parties

1
  • filerCIK 0001449753

Filing Metadata

Form type
4
Filed
Jun 29, 8:00 PM ET
Accepted
Jun 30, 6:47 AM ET
Size
10.4 KB